A startup didn't want to wait for doctors and insurers to get behind its breast-cancer risk prediction AI. So it's going directly to patients.

Utah plans to allow an AI product to evaluate patients and write new drug prescriptions without prior human review.

Proposed changes to the federal government’s health survey would undercount Americans with disabilities, advocates say.

I am honored to announce my candidacy for Director-General of the World Health Organization, nominated by the Republic of Botswana. I am deeply grateful to President ​Advocate Duma Gideon Boko and th...

Big shifts in health care policy could emerge depending on who wins the midterms, affecting hospitals and pharma companies.

Blockbuster GLP-1 drugs have transformed the lives of millions of people. Lately, they’re undergoing a makeover of their own.

New medical devices deemed "breakthrough" by the FDA are no longer automatically eligible for extra Medicare payments.

Advanced Research Projects Agency for Health is planning a total-lifespan research project on autism: A Q&A with its leader, Russell Shilling.

A new wave of radiology practices are aggressively embracing AI: developing and deploying it in-house, and marketing themselves as 'AI-native.'

Brittany Trang's subscriber-exclusive weekly newsletter unpacks the intersection of AI, health, and medicine.

A recently-launched Medicare experiment that pays for technology to help people manage chronic conditions is expanding.

The rushed launch of a Medicare pilot to use AI for prior authorization led to delayed care in some instances, new documents reveal.

“Nothing in the recent reporting about John Fetterman is medically surprising,” write Michael P.H. Stanley and Isaiah Kletenik.

“For thousands of families, the Sept. 11 attack did not end when the fires were extinguished. It simply changed form,” writes Raja Flores.

AI products from Cadence and Limbic are among four devices recently accepted into the FDA’s TEMPO pilot that will allow digital health companies to release products without marketing authorization.

Marc Tessier-Lavigne released new details from his research and travel in an attempt to refute allegations in a new book that he published fraudulent results.

New AI technology can help hospitals prevent controlled substances from being stolen, or abused by staff, but those tools aren't foolproof.

FDA expects to issue guidance on policies regarding generative AI devices, according to Rick Abramson, the agency’s head of digital health policy.

Reducing protein intake could increase human longevity, researchers recently suggested. That's a bad idea, for several reasons, experts say.

The American Cancer Society had an optics problem: its annual Wine and Spirits Industry's Gala. It decided to do something about it.

Immunologist Liz Marnik, who grew up unvaccinated, says shaming people who distrust science will do nothing to improve vaccine acceptance.

Several large health systems are rolling out AI chatbots to query patient records, because they can save time and increase diagnostic accuracy.

Doritos in the classic nacho cheese flavor have 27 ingredients, including not just familiar ones but also a number of additives and preservatives.

Colorado biotech Enveda reports preliminary results on a drug to help people maintain weight loss after GLP-1 use. Just don't call it exercise in a pill.

In its effort to lower drug prices, the White House has declared "promises made, promises kept." That's a narrative that doesn't reflect the full story.

A prominent AI startup has rolled out a virtual cell model, advancing the race to speed up science.

Epic Systems is the subject of a broad inquiry into its business practices, people who were contacted by FTC investigators told STAT.

Epic Systems is the subject of a broad inquiry into its business practices, people who were contacted by FTC investigators told STAT.

Commure, which develops and sells AI products to clinics, has terminated a program that paid for referrals to new customers.

Commure wants to automate health care's administrative tasks with AI. An inside look at the messy realities of the startup's ambitious quest.

Biotech startups in the U.S., France, and China are racing to bring new gene therapies for deafness by targeting different genetic mutations.

Nurses, who make up the largest part of the health care workforce, say clinical artificial intelligence poses a threat to their jobs, and patients.

Federal health officials invited tech companies and  lobbyists to closed-door meetings as they seek to boost adoption of clinical AI.

Some participants in a small trial showed improved tolerance to peanuts after fecal microbiome transplant.

Medicare is removing flexibilities that have allowed "breakthrough" medical devices to leapfrog qualifications for extra payments.

Educators want future physicians to be fluent in AI scribes, but they worry what off-loading clinical notes to AI could do to learning.

The U.S. Federal Trade Commission sued telehealth company Hims & Hers alleging business practices that agency says misled consumers.

At a highly anticipated Senate hearing, Anthony Fauci evoked his Fifth Amendment right to refuse to answer questions about the Covid-19 pandemic and its origins.

Biotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry.

As LLMs compete for doctors' attention, some developers say the science of benchmarking their AI tools for safety and accuracy is flawed.

Medicare is proposing to ban vendors from providing remote patient monitoring services on behalf of doctors.

Take this survey powered by surveymonkey.com. Create your own surveys for free.

Family caregivers of people with disabilities face a grim financial future as several states consider steep cuts to their wages.

A new secret-shopper study found that GLP-1 prescriptions from telehealth sites aren't often backed by appropriate clinical care.

A new secret-shopper study found that GLP-1 prescriptions from telehealth sites aren't often backed by appropriate clinical care.

FDA has granted breakthrough designation to two devices that use generative AI to interpret chest X-rays and draft the radiology reports.

A new study published in Nature uses artificial intelligence to identify people at high risk for sudden cardiac death, and pinpoints a possible reason.

The FDA's Breakthrough Device program is growing rapidly, but remains secretive. So STAT built a comprehensive database searchable by indication, manufacturer, regulatory pathway, and more.

An abandoned heart-failure trial offers a rare window into devices that the FDA deems "breakthrough" but never reach patients.